NCT00654238View on ClinicalTrials.gov

Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

December 31, 2010

Study Completion Date

March 31, 2011

Conditions
Metastatic Differentiated Thyroid CancerMetastatic Poorly Differentiated Thyroid CancerMetastatic Anaplastic Thyroid CancerMetastatic Medullary Thyroid Cancer
Interventions
DRUG

sorafenib

400mg PO BID daily

Trial Locations (1)

19104

University of Pennsylvania - Abramson Comprehensive Cancer Center, Philadelphia

All Listed Sponsors
lead

University of Pennsylvania

OTHER

NCT00654238 - Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer | Biotech Hunter | Biotech Hunter